IDXX 151.39 Idexx Laboratories $IDXX Hit a 52 week
Post# of 46498
Posted On: 11/14/2014 12:46:22 PM
IDXX 151.39 Idexx Laboratories $IDXX Hit a 52 week high of 152.08 Closing the day 09:44 at 151.39 -1.11 -0.73% With a day low of 150.97 and a total volume of 21,784.
IDXX Recent Posts: http://investorshangout.com/IDEXX-Laboratorie...DXX-54421/
IDXX Idexx Laboratories Recent Headline News
Exactech (EXAC) Down to Strong Sell On Dismal Q3 Results - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Nov 13, 12:30PM CST
Exactech Inc.'s (EXAC) lackluster third-quarter 2014 results (reported on Oct 21), with both earnings and revenues missing expectations, have set a negative earnings estimate revision trend for the company.
ICUI: 85.97 (+1.02), BABY: 33.73 (-0.58), EXAC: 22.35 (-0.12), IDXX: 150.81 (-1.69)
Uptrend Call Working As Idexx Laboratories Stock Rises 24.1% (IDXX)
Comtex SmarTrend(R) - Wed Nov 12, 9:56AM CST
SmarTrend identified an Uptrend for Idexx Laboratories (NASDAQ:IDXX) on October 21st, 2014 at $122.52. In approximately 3 weeks, Idexx Laboratories has returned 24.07% as of today's recent price of $152.00.
IDXX: 150.81 (-1.69)
Trade-Ideas: Idexx Laboratories (IDXX) Is Today's Strong And Under The Radar Stock
at The Street - Tue Nov 11, 9:42AM CST
Trade-Ideas LLC identified Idexx Laboratories (IDXX) as a strong and under the radar candidate
IDXX: 150.81 (-1.69)
SmarTrend Watching for Potential Pullback in Shares of Idexx Laboratories After 1.39% Gain
Comtex SmarTrend(R) - Mon Nov 10, 5:17PM CST
Idexx Laboratories (NASDAQ:IDXX) traded in a range yesterday that spanned from a low of $144.18 to a high of $147.67. Yesterday, the shares gained 1.4%, which took the trading range above the 3-day high of $146.00 on volume of 560,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
IDXX: 150.81 (-1.69)
Idexx Laboratories Earnings Hindsight: Up 7.4% in Last 17 Days (IDXX)
Comtex SmarTrend(R) - Mon Nov 10, 1:31PM CST
17 days ago, on October 24th, 2014, Idexx Laboratories (NASDAQ:IDXX) reported its earnings. Analysts, on average, expected earnings of $0.86 per share on sales of $371.3 million. Idexx Laboratories actually reported earnings of $1.05 per share on sales of $383.5 million, beating EPS estimates by $0.19 and beating revenue estimates by $12.2 million. Since the company's report, shares of Idexx Laboratories have risen from $135.20 to $145.16, representing a gain of 7.4% in the past 17 days.
IDXX: 150.81 (-1.69)
Idexx Laboratories Has Returned 17.5% Since SmarTrend Recommendation (IDXX)
Comtex SmarTrend(R) - Wed Nov 05, 9:25AM CST
SmarTrend identified an Uptrend for Idexx Laboratories (NASDAQ:IDXX) on October 21st, 2014 at $122.52. In approximately 2 weeks, Idexx Laboratories has returned 17.52% as of today's recent price of $143.98.
IDXX: 150.81 (-1.69)
Comparing America's 3 Largest Diagnostic Substances Companies
Joseph Cafariello - at Seeking Alpha - Mon Nov 03, 12:03PM CST
QDEL: 28.25 (-0.09), NEOG: 42.99 (-1.06), IDXX: 150.81 (-1.69)
Quarterly Earnings Releases and Recognitions - Research Reports on GlaxoSmithKline, IDEXX, BioMarin, GE and Lockheed Martin
PR Newswire - Wed Oct 29, 8:30AM CDT
Today, Analysts Review released its research reports regarding GlaxoSmithKline plc (NYSE: GSK), IDEXX Laboratories, Inc. (NASDAQ: IDXX), BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), General Electric Company (NYSE: GE) and Lockheed Martin Corporation (NYSE: LMT). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/7542-100free.
LMT: 186.43 (-1.54), GE: 26.44 (+0.02), BMRN: 84.08 (-3.84), IDXX: 150.81 (-1.69), GSK: 45.70 (+0.04), NVS: 93.99 (-0.39)
IDEXX Laboratories (IDXX) Shares March Higher, Can It Continue? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Oct 29, 7:57AM CDT
IDEXX Laboratories (IDXX) Shares March Higher, Can It Continue?
IDXX: 150.81 (-1.69)
IDEXX Tops Q3 Earnings and Revenues; Guidance Revised - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Oct 28, 12:10PM CDT
Since the news release, IDEXX's (IDXX) share price has climbed 9.8% to eventually close at $138.76 yesterday.
ATEC: 1.38 (+0.02), EW: 124.27 (-0.28), IDXX: 150.81 (-1.69), ANGO: 16.67 (-0.19)
Today's Strong And Under The Radar Stock Is Idexx Laboratories (IDXX)
at The Street - Tue Oct 28, 8:51AM CDT
Trade-Ideas LLC identified Idexx Laboratories (IDXX) as a strong and under the radar candidate
IDXX: 150.81 (-1.69)
IDEXX Laboratories, Inc. Is as Fit as a Butcher's Dog
Brian Orelli, The Motley Fool - Motley Fool - Fri Oct 24, 6:56PM CDT
Shares of IDEXX Laboratories jumped 7% today after reporting a solid third quarter, raising 2014 guidance, and issuing 2015 guidance that looks even better. The stock of the animal health-test provider soared to a 52-week and all-time high. ...
IDXX: 150.81 (-1.69)
Idexx Laboratories Set to Possibly Pullback After Yesterday's Rally of 7.00%
Comtex SmarTrend(R) - Fri Oct 24, 4:12PM CDT
Idexx Laboratories (NASDAQ:IDXX) traded in a range yesterday that spanned from a low of $130.06 to a high of $140.42. Yesterday, the shares gained 7.0%, which took the trading range above the 3-day high of $126.42 on volume of 1.8 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
IDXX: 150.81 (-1.69)
IDEXX Laboratories' (IDXX) CEO Jon Ayers on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Fri Oct 24, 1:02PM CDT
IDXX: 150.81 (-1.69)
Idexx Q3 income up 14%
Seeking Alpha - at Seeking Alpha - Fri Oct 24, 10:00AM CDT
IDXX: 150.81 (-1.69)
Idexx beats Street 3Q forecasts
Automated Insights - Fri Oct 24, 6:27AM CDT
WESTBROOK, Maine (AP) _ Idexx Laboratories Inc. (IDXX) on Friday reported net income of $52.1 million in its third quarter.
IDXX: 150.81 (-1.69)
IDEXX Laboratories beats by $0.15, beats on revenue
Seeking Alpha - at Seeking Alpha - Fri Oct 24, 6:07AM CDT
IDXX: 150.81 (-1.69)
IDEXX Laboratories Announces Third Quarter Results
PR Newswire - Fri Oct 24, 6:00AM CDT
IDEXX Laboratories, Inc. (NASDAQ: IDXX) today reported that revenues for the third quarter of 2014 increased 13% versus the prior year period to $384 million. Organic revenue growth1 for the third quarter of 2014 versus the prior year period was also 13%, or 11% normalized for changes in distributor inventory2. Earnings per diluted share ("EPS"
for the quarter ended September 30, 2014 increased 21% from the prior year period to $1.03. Adjusted EPS3 for the quarter was $1.05.
IDXX: 150.81 (-1.69)
Notable earnings before Friday’s open
Seeking Alpha - at Seeking Alpha - Thu Oct 23, 4:30PM CDT
WYN: 79.71 (-0.39), SFE: 19.33 (-0.04), F: 15.10 (+0.17), OCR: 69.38 (+0.18), B: 37.31 (+0.25), SXC: 22.48 (-0.16), VTR: 68.69 (-0.82), UPS: 107.01 (-0.78), DLPH: 70.78 (+0.07), CHH: 52.62 (-0.53), LYB: 88.39 (+0.45), COG: 33.30 (+0.60), SHPG: 202.07 (-0.35), TCB: 15.93 (-0.01), AVY: 47.79 (-0.30), AAN: 27.32 (-0.19), MGLN: 61.08 (-0.37), STT: 76.35 (-0.13), FNFG: 8.08 (+0.27), IMGN: 9.27 (-0.19), EDU: 22.11 (+0.02), BMY: 57.72 (-0.08), DTE: 79.93 (+0.15), LEA: 93.30 (-0.07), MCO: 100.88 (-0.02), FLIR: 32.30 (-0.14), IMS: 24.73 (-0.02), LPNT: 64.22 (-0.03), ERIC: 12.08 (+0.02), PG: 88.50 (-0.10), IDXX: 150.81 (-1.69), WBC: 100.80 (-0.29), NDAQ: 43.90 (+0.11), CL: 67.88 (-0.41)
Oracle Enterprise Manager Enables Seamless IT Management and Visibility for IDEXX Laboratories
Marketwired - Wed Oct 15, 7:04AM CDT
Oracle (NYSE: ORCL)
IDXX: 150.81 (-1.69), ORCL: 40.71 (-0.01)
IDXX Recent Posts: http://investorshangout.com/IDEXX-Laboratorie...DXX-54421/
IDXX Idexx Laboratories Recent Headline News
Exactech (EXAC) Down to Strong Sell On Dismal Q3 Results - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Nov 13, 12:30PM CST
Exactech Inc.'s (EXAC) lackluster third-quarter 2014 results (reported on Oct 21), with both earnings and revenues missing expectations, have set a negative earnings estimate revision trend for the company.
ICUI: 85.97 (+1.02), BABY: 33.73 (-0.58), EXAC: 22.35 (-0.12), IDXX: 150.81 (-1.69)
Uptrend Call Working As Idexx Laboratories Stock Rises 24.1% (IDXX)
Comtex SmarTrend(R) - Wed Nov 12, 9:56AM CST
SmarTrend identified an Uptrend for Idexx Laboratories (NASDAQ:IDXX) on October 21st, 2014 at $122.52. In approximately 3 weeks, Idexx Laboratories has returned 24.07% as of today's recent price of $152.00.
IDXX: 150.81 (-1.69)
Trade-Ideas: Idexx Laboratories (IDXX) Is Today's Strong And Under The Radar Stock
at The Street - Tue Nov 11, 9:42AM CST
Trade-Ideas LLC identified Idexx Laboratories (IDXX) as a strong and under the radar candidate
IDXX: 150.81 (-1.69)
SmarTrend Watching for Potential Pullback in Shares of Idexx Laboratories After 1.39% Gain
Comtex SmarTrend(R) - Mon Nov 10, 5:17PM CST
Idexx Laboratories (NASDAQ:IDXX) traded in a range yesterday that spanned from a low of $144.18 to a high of $147.67. Yesterday, the shares gained 1.4%, which took the trading range above the 3-day high of $146.00 on volume of 560,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
IDXX: 150.81 (-1.69)
Idexx Laboratories Earnings Hindsight: Up 7.4% in Last 17 Days (IDXX)
Comtex SmarTrend(R) - Mon Nov 10, 1:31PM CST
17 days ago, on October 24th, 2014, Idexx Laboratories (NASDAQ:IDXX) reported its earnings. Analysts, on average, expected earnings of $0.86 per share on sales of $371.3 million. Idexx Laboratories actually reported earnings of $1.05 per share on sales of $383.5 million, beating EPS estimates by $0.19 and beating revenue estimates by $12.2 million. Since the company's report, shares of Idexx Laboratories have risen from $135.20 to $145.16, representing a gain of 7.4% in the past 17 days.
IDXX: 150.81 (-1.69)
Idexx Laboratories Has Returned 17.5% Since SmarTrend Recommendation (IDXX)
Comtex SmarTrend(R) - Wed Nov 05, 9:25AM CST
SmarTrend identified an Uptrend for Idexx Laboratories (NASDAQ:IDXX) on October 21st, 2014 at $122.52. In approximately 2 weeks, Idexx Laboratories has returned 17.52% as of today's recent price of $143.98.
IDXX: 150.81 (-1.69)
Comparing America's 3 Largest Diagnostic Substances Companies
Joseph Cafariello - at Seeking Alpha - Mon Nov 03, 12:03PM CST
QDEL: 28.25 (-0.09), NEOG: 42.99 (-1.06), IDXX: 150.81 (-1.69)
Quarterly Earnings Releases and Recognitions - Research Reports on GlaxoSmithKline, IDEXX, BioMarin, GE and Lockheed Martin
PR Newswire - Wed Oct 29, 8:30AM CDT
Today, Analysts Review released its research reports regarding GlaxoSmithKline plc (NYSE: GSK), IDEXX Laboratories, Inc. (NASDAQ: IDXX), BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), General Electric Company (NYSE: GE) and Lockheed Martin Corporation (NYSE: LMT). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/7542-100free.
LMT: 186.43 (-1.54), GE: 26.44 (+0.02), BMRN: 84.08 (-3.84), IDXX: 150.81 (-1.69), GSK: 45.70 (+0.04), NVS: 93.99 (-0.39)
IDEXX Laboratories (IDXX) Shares March Higher, Can It Continue? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Oct 29, 7:57AM CDT
IDEXX Laboratories (IDXX) Shares March Higher, Can It Continue?
IDXX: 150.81 (-1.69)
IDEXX Tops Q3 Earnings and Revenues; Guidance Revised - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Oct 28, 12:10PM CDT
Since the news release, IDEXX's (IDXX) share price has climbed 9.8% to eventually close at $138.76 yesterday.
ATEC: 1.38 (+0.02), EW: 124.27 (-0.28), IDXX: 150.81 (-1.69), ANGO: 16.67 (-0.19)
Today's Strong And Under The Radar Stock Is Idexx Laboratories (IDXX)
at The Street - Tue Oct 28, 8:51AM CDT
Trade-Ideas LLC identified Idexx Laboratories (IDXX) as a strong and under the radar candidate
IDXX: 150.81 (-1.69)
IDEXX Laboratories, Inc. Is as Fit as a Butcher's Dog
Brian Orelli, The Motley Fool - Motley Fool - Fri Oct 24, 6:56PM CDT
Shares of IDEXX Laboratories jumped 7% today after reporting a solid third quarter, raising 2014 guidance, and issuing 2015 guidance that looks even better. The stock of the animal health-test provider soared to a 52-week and all-time high. ...
IDXX: 150.81 (-1.69)
Idexx Laboratories Set to Possibly Pullback After Yesterday's Rally of 7.00%
Comtex SmarTrend(R) - Fri Oct 24, 4:12PM CDT
Idexx Laboratories (NASDAQ:IDXX) traded in a range yesterday that spanned from a low of $130.06 to a high of $140.42. Yesterday, the shares gained 7.0%, which took the trading range above the 3-day high of $126.42 on volume of 1.8 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
IDXX: 150.81 (-1.69)
IDEXX Laboratories' (IDXX) CEO Jon Ayers on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Fri Oct 24, 1:02PM CDT
IDXX: 150.81 (-1.69)
Idexx Q3 income up 14%
Seeking Alpha - at Seeking Alpha - Fri Oct 24, 10:00AM CDT
IDXX: 150.81 (-1.69)
Idexx beats Street 3Q forecasts
Automated Insights - Fri Oct 24, 6:27AM CDT
WESTBROOK, Maine (AP) _ Idexx Laboratories Inc. (IDXX) on Friday reported net income of $52.1 million in its third quarter.
IDXX: 150.81 (-1.69)
IDEXX Laboratories beats by $0.15, beats on revenue
Seeking Alpha - at Seeking Alpha - Fri Oct 24, 6:07AM CDT
IDXX: 150.81 (-1.69)
IDEXX Laboratories Announces Third Quarter Results
PR Newswire - Fri Oct 24, 6:00AM CDT
IDEXX Laboratories, Inc. (NASDAQ: IDXX) today reported that revenues for the third quarter of 2014 increased 13% versus the prior year period to $384 million. Organic revenue growth1 for the third quarter of 2014 versus the prior year period was also 13%, or 11% normalized for changes in distributor inventory2. Earnings per diluted share ("EPS"
for the quarter ended September 30, 2014 increased 21% from the prior year period to $1.03. Adjusted EPS3 for the quarter was $1.05. IDXX: 150.81 (-1.69)
Notable earnings before Friday’s open
Seeking Alpha - at Seeking Alpha - Thu Oct 23, 4:30PM CDT
WYN: 79.71 (-0.39), SFE: 19.33 (-0.04), F: 15.10 (+0.17), OCR: 69.38 (+0.18), B: 37.31 (+0.25), SXC: 22.48 (-0.16), VTR: 68.69 (-0.82), UPS: 107.01 (-0.78), DLPH: 70.78 (+0.07), CHH: 52.62 (-0.53), LYB: 88.39 (+0.45), COG: 33.30 (+0.60), SHPG: 202.07 (-0.35), TCB: 15.93 (-0.01), AVY: 47.79 (-0.30), AAN: 27.32 (-0.19), MGLN: 61.08 (-0.37), STT: 76.35 (-0.13), FNFG: 8.08 (+0.27), IMGN: 9.27 (-0.19), EDU: 22.11 (+0.02), BMY: 57.72 (-0.08), DTE: 79.93 (+0.15), LEA: 93.30 (-0.07), MCO: 100.88 (-0.02), FLIR: 32.30 (-0.14), IMS: 24.73 (-0.02), LPNT: 64.22 (-0.03), ERIC: 12.08 (+0.02), PG: 88.50 (-0.10), IDXX: 150.81 (-1.69), WBC: 100.80 (-0.29), NDAQ: 43.90 (+0.11), CL: 67.88 (-0.41)
Oracle Enterprise Manager Enables Seamless IT Management and Visibility for IDEXX Laboratories
Marketwired - Wed Oct 15, 7:04AM CDT
Oracle (NYSE: ORCL)
IDXX: 150.81 (-1.69), ORCL: 40.71 (-0.01)
(0)
(0)Scroll down for more posts ▼